Rising Corporate Tax Inversion “Fever” Unlikely To Lower Medical Product Prices
This article was originally published in The Tan Sheet
Executive Summary
Finance Committee Chairman Wyden questions the suggestion that pharmaceutical manufacturers’ corporate tax inversions could lead to lower health care costs in the U.S. Experts urge Congress to eliminate or alter inversions or other methods firms use to lessen their tax burdens under the current code.